KR20220090492A - 바이시클릭 cx3cr1 수용체 작용제 - Google Patents
바이시클릭 cx3cr1 수용체 작용제 Download PDFInfo
- Publication number
- KR20220090492A KR20220090492A KR1020227005729A KR20227005729A KR20220090492A KR 20220090492 A KR20220090492 A KR 20220090492A KR 1020227005729 A KR1020227005729 A KR 1020227005729A KR 20227005729 A KR20227005729 A KR 20227005729A KR 20220090492 A KR20220090492 A KR 20220090492A
- Authority
- KR
- South Korea
- Prior art keywords
- methyl
- stereoisomer
- salt
- alkyl
- hydrogen
- Prior art date
Links
Images
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
- C07D409/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/16—Amides, e.g. hydroxamic acids
- A61K31/165—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide
- A61K31/166—Amides, e.g. hydroxamic acids having aromatic rings, e.g. colchicine, atenolol, progabide having the carbon of a carboxamide group directly attached to the aromatic ring, e.g. procainamide, procarbazine, metoclopramide, labetalol
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
- A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
- A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
- A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
- A61K31/445—Non condensed piperidines, e.g. piperocaine
- A61K31/4523—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems
- A61K31/4535—Non condensed piperidines, e.g. piperocaine containing further heterocyclic ring systems containing a heterocyclic ring having sulfur as a ring hetero atom, e.g. pizotifen
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C233/00—Carboxylic acid amides
- C07C233/64—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings
- C07C233/77—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups
- C07C233/78—Carboxylic acid amides having carbon atoms of carboxamide groups bound to carbon atoms of six-membered aromatic rings having the nitrogen atom of at least one of the carboxamide groups bound to a carbon atom of a hydrocarbon radical substituted by amino groups with the substituted hydrocarbon radical bound to the nitrogen atom of the carboxamide group by an acyclic carbon atom
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/78—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D333/00—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom
- C07D333/50—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems
- C07D333/78—Heterocyclic compounds containing five-membered rings having one sulfur atom as the only ring hetero atom condensed with carbocyclic rings or ring systems condensed with rings other than six-membered or with ring systems containing such rings
- C07D333/80—Seven-membered rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
- C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
- C07D491/044—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring
- C07D491/048—Ortho-condensed systems with only one oxygen atom as ring hetero atom in the oxygen-containing ring the oxygen-containing ring being five-membered
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2601/00—Systems containing only non-condensed rings
- C07C2601/06—Systems containing only non-condensed rings with a five-membered ring
- C07C2601/08—Systems containing only non-condensed rings with a five-membered ring the ring being saturated
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
- C07C2602/00—Systems containing two condensed rings
- C07C2602/02—Systems containing two condensed rings the rings having only two atoms in common
- C07C2602/14—All rings being cycloaliphatic
- C07C2602/32—All rings being cycloaliphatic the ring system containing at least eleven carbon atoms
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Engineering & Computer Science (AREA)
- Neurosurgery (AREA)
- Biomedical Technology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Neurology (AREA)
- Pain & Pain Management (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Rheumatology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Heterocyclic Carbon Compounds Containing A Hetero Ring Having Oxygen Or Sulfur (AREA)
- Plural Heterocyclic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
Applications Claiming Priority (3)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201962877660P | 2019-07-23 | 2019-07-23 | |
US62/877,660 | 2019-07-23 | ||
PCT/US2020/043258 WO2021016449A1 (fr) | 2019-07-23 | 2020-07-23 | Agonistes bicycliques du récepteur |
Publications (1)
Publication Number | Publication Date |
---|---|
KR20220090492A true KR20220090492A (ko) | 2022-06-29 |
Family
ID=74189124
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
KR1020227005729A KR20220090492A (ko) | 2019-07-23 | 2020-07-23 | 바이시클릭 cx3cr1 수용체 작용제 |
Country Status (11)
Country | Link |
---|---|
US (3) | US11155538B2 (fr) |
EP (1) | EP4003972A4 (fr) |
JP (1) | JP2022541627A (fr) |
KR (1) | KR20220090492A (fr) |
CN (1) | CN114929681B (fr) |
AU (1) | AU2020316080A1 (fr) |
BR (1) | BR112022001184A2 (fr) |
CA (1) | CA3148454A1 (fr) |
IL (1) | IL290024A (fr) |
MX (1) | MX2022000917A (fr) |
WO (1) | WO2021016449A1 (fr) |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
KR20220090492A (ko) | 2019-07-23 | 2022-06-29 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 바이시클릭 cx3cr1 수용체 작용제 |
Family Cites Families (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SE0401969D0 (sv) * | 2004-08-02 | 2004-08-02 | Astrazeneca Ab | Piperidine derivatives |
WO2009086303A2 (fr) * | 2007-12-21 | 2009-07-09 | University Of Rochester | Procédé permettant de modifier la durée de vie d'organismes eucaryotes |
UY32443A (es) * | 2009-02-13 | 2010-09-30 | Sanofi Aventis | Nuevos tetrahidronaftalenos, procesos para su preparación y uso de los mismos como medicamento. |
WO2012012322A1 (fr) | 2010-07-19 | 2012-01-26 | Millennium Pharmaceuticals, Inc. | Acides hydroxamiques substitués et leurs utilisations |
WO2012078633A2 (fr) * | 2010-12-07 | 2012-06-14 | Philadelphia Health And Education Corporation, D/B/A Drexel University College Of Medicene | Méthodes d'inhibition de la métastase d'un cancer |
CN104744451A (zh) * | 2013-12-30 | 2015-07-01 | 中国科学院上海药物研究所 | 一种1-(3-氨基丙基)取代环状胺类化合物、其制备方法、药物组合物及用途 |
CA2946062C (fr) * | 2014-04-17 | 2023-02-28 | Institut Pasteur Korea | Composes pour traiter des infections virales |
WO2018204370A1 (fr) * | 2017-05-02 | 2018-11-08 | Drexel University | Antagonistes de cx3cr1 à petites molécules, et procédés les utilisant |
KR20220090492A (ko) | 2019-07-23 | 2022-06-29 | 더 보드 오브 리젠츠 오브 더 유니버시티 오브 텍사스 시스템 | 바이시클릭 cx3cr1 수용체 작용제 |
-
2020
- 2020-07-23 KR KR1020227005729A patent/KR20220090492A/ko unknown
- 2020-07-23 WO PCT/US2020/043258 patent/WO2021016449A1/fr unknown
- 2020-07-23 AU AU2020316080A patent/AU2020316080A1/en active Pending
- 2020-07-23 CA CA3148454A patent/CA3148454A1/fr active Pending
- 2020-07-23 JP JP2022504301A patent/JP2022541627A/ja active Pending
- 2020-07-23 US US16/937,005 patent/US11155538B2/en active Active
- 2020-07-23 MX MX2022000917A patent/MX2022000917A/es unknown
- 2020-07-23 BR BR112022001184A patent/BR112022001184A2/pt not_active Application Discontinuation
- 2020-07-23 CN CN202080066180.7A patent/CN114929681B/zh active Active
- 2020-07-23 EP EP20844991.8A patent/EP4003972A4/fr active Pending
-
2021
- 2021-09-22 US US17/481,653 patent/US11958839B2/en active Active
-
2022
- 2022-01-20 IL IL290024A patent/IL290024A/en unknown
-
2023
- 2023-09-19 US US18/470,029 patent/US20240150332A1/en active Pending
Also Published As
Publication number | Publication date |
---|---|
CN114929681B (zh) | 2024-05-14 |
CA3148454A1 (fr) | 2021-01-28 |
JP2022541627A (ja) | 2022-09-26 |
IL290024A (en) | 2022-03-01 |
EP4003972A4 (fr) | 2023-07-12 |
US20220259191A1 (en) | 2022-08-18 |
WO2021016449A1 (fr) | 2021-01-28 |
US11155538B2 (en) | 2021-10-26 |
AU2020316080A1 (en) | 2022-03-03 |
MX2022000917A (es) | 2022-04-07 |
US11958839B2 (en) | 2024-04-16 |
US20210024510A1 (en) | 2021-01-28 |
EP4003972A1 (fr) | 2022-06-01 |
CN114929681A (zh) | 2022-08-19 |
US20240150332A1 (en) | 2024-05-09 |
BR112022001184A2 (pt) | 2022-03-15 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
US10167281B2 (en) | Substituted thiazole or oxazole P2X7 receptor antagonists | |
US20230010299A1 (en) | Heterocyclic trpml1 agonists | |
US20240150332A1 (en) | Bicyclic cx3cr1 receptor agonists | |
NZ588589A (en) | Novel class of spiro piperidines for the treatment of neurodegenerative diseases | |
ES2911049T3 (es) | Antagonistas heterocíclicos de P2X7 | |
US10669267B2 (en) | Substituted N-[2-(4-phenoxypiperidin-1-yl)-2-(1,3-thiazol-5-yl)ethyl]benzamide and N-[2-(4-benzyloxypiperidin-1-yl)-2-(1,3-thiazol-5-yl)ethyl]benzamide derivatives P2X7 receptor antagonists | |
EP3290417A1 (fr) | 2-chloro-n-[2-(1,3-thiazol-5-yl)ethyl]-5-(5-fluoropyrimidin-2-yl)-benzamides et leur utilisation en tant qu'antagonistes du récepteur p2x7 | |
CN117881675A (zh) | 2,4-二氢-3h-1,2,4-三唑-3-酮p2x7拮抗剂 |